EMVision Advances FDA Trial and Pre-Hospital Studies with $18.4m Cash Reserve
EMVision Medical Devices has ramped up recruitment in its pivotal FDA trial across eight hospitals and is nearing results from multiple pre-hospital studies, all while bolstering its cash position with a $3.8 million R&D tax refund and $6.6 million in grant funding.
- Eight hospitals actively recruiting in FDA pivotal trial with no device-related adverse events
- Pre-hospital feasibility studies for First Responder device nearing completion
- Received $3.8 million R&D tax refund for FY25 and $0.4 million milestone grant payment
- Cash reserves stand at $18.4 million with $6.6 million in remaining non-dilutive grant funding
- Continuous innovation study progressing with AI model refinement for stroke detection
Pivotal Trial Gains Momentum Across Leading Hospitals
EMVision Medical Devices (ASX:EMV) has intensified recruitment in its pivotal (validation) trial aimed at securing FDA De Novo clearance for its emu™ point-of-care brain scanner. The trial now features eight leading academic and teaching hospitals, including Mayo Clinic in Florida, Mt Sinai in New York, UCLA Health in California, and Royal Melbourne Hospital in Australia. These sites are actively ramping up patient screening, supported by initiatives such as broader clinical team engagement and extended after-hours coverage. Notably, the emu™ device has been integrated safely into acute stroke workflows with no device-related adverse events reported to date.
This progress builds on EMVision’s growing clinical profile, highlighted by a presentation at the Novel Acute Brain Injury Conference (NABI-Con) 2026 in Houston, where Dr Aaron Gusdon showcased the company's use of artificial intelligence for portable stroke diagnosis. Additionally, a leading US academic centre is preparing a publication on early clinical experiences with the device, further boosting international awareness.
Pre-Hospital Device Studies Nearing Key Milestones
EMVision’s First Responder program, a miniaturised version of the emu™ designed for pre-hospital use, is advancing rapidly through multiple feasibility and usability studies. The aeromedical retrieval study with the Royal Flying Doctor Service and South Australian Ambulance Service is expected to complete recruitment this quarter, having demonstrated ease of use in fixed-wing aircraft and high patient acceptance.
Meanwhile, the Mobile Stroke Unit study in collaboration with Ambulance Victoria and Royal Melbourne Hospital is also wrapping up its first stage, offering rare insights into integrating the device within ultra-early stroke response pathways. Complementing these, a road ambulance feasibility study is in advanced planning, focusing on the device’s primary use environment, paramedic field deployment.
Strong Financial Position Supported by Grants and Tax Incentives
EMVision’s financial footing remains robust, closing the quarter with $18.4 million in cash reserves and access to $6.6 million in remaining non-dilutive grant funding. The company received a $3.8 million R&D tax refund for FY25, up from $2.1 million the previous year, and secured approval to claim rebates on eligible overseas R&D expenditures through to 2027, as detailed in a recent update on its funding boost.
Operational cash flow was positive this quarter, with $0.931 million net inflow despite ongoing investment in research and development ($1.083 million) and staff costs ($1.836 million). These expenditures reflect continued efforts in clinical trial activities, product development, and regulatory preparations. The company also received a $0.4 million milestone payment under the CRC-P grant for its Regional Benefits Study, which is on track for launch in the second half of 2026.
Innovation and Expansion of AI Capabilities
Beyond clinical trials, EMVision is advancing its Continuous Innovation Study, which involves steady enrolment across multiple sites and the establishment of a data processing pipeline. This infrastructure supports ongoing artificial intelligence model refinement, aiming to enhance detection of acute ischemia and large vessel occlusion (LVO), and lays the groundwork for future indications such as traumatic brain injury.
With multiple hospital sites actively recruiting, pre-hospital studies nearing completion, and a strong balance sheet bolstered by recent grants and tax incentives, EMVision is positioning itself for a critical phase of regulatory submission and commercialisation. The company’s ability to integrate AI into portable neurodiagnostics could mark a significant shift in stroke and brain injury care pathways.
Bottom Line?
EMVision’s expanding clinical trial footprint and robust funding position set the stage for upcoming FDA submission and potential market entry, though trial outcomes and regulatory timing remain key uncertainties.
Questions in the middle?
- Will the pivotal trial recruitment maintain momentum to meet planned FDA submission timelines?
- How will insights from pre-hospital studies influence the final design and deployment strategy of the First Responder device?
- What impact will ongoing AI model refinements have on diagnostic accuracy and potential new clinical indications?
